Etoposide and split-dose cisplatin in bronchogenic carcinoma

R. C. Lauer, W. B. Fisher, K. Pennington, R. Ansari, L. H. Einhorn, P. J. Loehrer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The Hoosier Oncology Group (HOG) treated 13 patients with bronchogenic carcinoma and an innovative schedule of cisplatin and VP-16. Unexpected toxicity was noted, and five deaths secondary to granulocytopenia and septic shock and three episodes of renal failure. Despite early closure of this study, we conclude that this schedule of cisplatin and VP-16 results in greater toxicity than comparable dosages in a more routine schedule.

Original languageEnglish (US)
Pages (from-to)634-635
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number6
DOIs
StatePublished - Jan 1 1988

Fingerprint

Bronchogenic Carcinoma
Etoposide
Cisplatin
Appointments and Schedules
Agranulocytosis
Septic Shock
Renal Insufficiency

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Etoposide and split-dose cisplatin in bronchogenic carcinoma. / Lauer, R. C.; Fisher, W. B.; Pennington, K.; Ansari, R.; Einhorn, L. H.; Loehrer, P. J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. 6, 01.01.1988, p. 634-635.

Research output: Contribution to journalArticle

Lauer, R. C. ; Fisher, W. B. ; Pennington, K. ; Ansari, R. ; Einhorn, L. H. ; Loehrer, P. J. / Etoposide and split-dose cisplatin in bronchogenic carcinoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1988 ; Vol. 11, No. 6. pp. 634-635.
@article{d00aa09181c6495d934c5bc7d267b836,
title = "Etoposide and split-dose cisplatin in bronchogenic carcinoma",
abstract = "The Hoosier Oncology Group (HOG) treated 13 patients with bronchogenic carcinoma and an innovative schedule of cisplatin and VP-16. Unexpected toxicity was noted, and five deaths secondary to granulocytopenia and septic shock and three episodes of renal failure. Despite early closure of this study, we conclude that this schedule of cisplatin and VP-16 results in greater toxicity than comparable dosages in a more routine schedule.",
author = "Lauer, {R. C.} and Fisher, {W. B.} and K. Pennington and R. Ansari and Einhorn, {L. H.} and Loehrer, {P. J.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1097/00000421-198812000-00008",
language = "English (US)",
volume = "11",
pages = "634--635",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Etoposide and split-dose cisplatin in bronchogenic carcinoma

AU - Lauer, R. C.

AU - Fisher, W. B.

AU - Pennington, K.

AU - Ansari, R.

AU - Einhorn, L. H.

AU - Loehrer, P. J.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The Hoosier Oncology Group (HOG) treated 13 patients with bronchogenic carcinoma and an innovative schedule of cisplatin and VP-16. Unexpected toxicity was noted, and five deaths secondary to granulocytopenia and septic shock and three episodes of renal failure. Despite early closure of this study, we conclude that this schedule of cisplatin and VP-16 results in greater toxicity than comparable dosages in a more routine schedule.

AB - The Hoosier Oncology Group (HOG) treated 13 patients with bronchogenic carcinoma and an innovative schedule of cisplatin and VP-16. Unexpected toxicity was noted, and five deaths secondary to granulocytopenia and septic shock and three episodes of renal failure. Despite early closure of this study, we conclude that this schedule of cisplatin and VP-16 results in greater toxicity than comparable dosages in a more routine schedule.

UR - http://www.scopus.com/inward/record.url?scp=0023700856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023700856&partnerID=8YFLogxK

U2 - 10.1097/00000421-198812000-00008

DO - 10.1097/00000421-198812000-00008

M3 - Article

C2 - 3189229

AN - SCOPUS:0023700856

VL - 11

SP - 634

EP - 635

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -